BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27882343)

  • 1. Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis.
    Li C; Li N; Liu X; Zhang EY; Sun Y; Masuda K; Li J; Sun J; Morrison T; Li X; Chen Y; Wang J; Karim NA; Zhang Y; Blenis J; Reginato MJ; Henske EP; Yu JJ
    JCI Insight; 2016 Nov; 1(19):e86629. PubMed ID: 27882343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.
    Sun Y; Zhang E; Lao T; Pereira AM; Li C; Xiong L; Morrison T; Haley KJ; Zhou X; Yu JJ
    Horm Cancer; 2014 Oct; 5(5):284-98. PubMed ID: 25069840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
    Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
    Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.
    Li X; Liu X; Zhang L; Li C; Zhang E; Ma W; Fan Q; Yu JJ
    Oncotarget; 2017 May; 8(22):36628-36638. PubMed ID: 28410230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.
    Li C; Zhou X; Sun Y; Zhang E; Mancini JD; Parkhitko A; Morrison TA; Silverman EK; Henske EP; Yu JJ
    Am J Respir Cell Mol Biol; 2013 Jul; 49(1):135-42. PubMed ID: 23526212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
    Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
    PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.
    Liu F; Lunsford EP; Tong J; Ashitate Y; Gibbs SL; Yu J; Choi HS; Henske EP; Frangioni JV
    PLoS One; 2012; 7(6):e38589. PubMed ID: 22719903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
    Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
    Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
    Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
    Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells.
    Yu JJ; Robb VA; Morrison TA; Ariazi EA; Karbowniczek M; Astrinidis A; Wang C; Hernandez-Cuebas L; Seeholzer LF; Nicolas E; Hensley H; Jordan VC; Walker CL; Henske EP
    Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2635-40. PubMed ID: 19202070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
    Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
    Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.
    Steagall WK; Pacheco-Rodriguez G; Glasgow CG; Ikeda Y; Lin JP; Zheng G; Moss J
    Am J Pathol; 2013 Sep; 183(3):938-50. PubMed ID: 23867796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.
    Tyryshkin A; Bhattacharya A; Eissa NT
    Cancer Res; 2014 Apr; 74(7):1996-2005. PubMed ID: 24691995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.
    Pacheco-Rodriguez G; Steagall WK; Crooks DM; Stevens LA; Hashimoto H; Li S; Wang JA; Darling TN; Moss J
    Cancer Res; 2007 Nov; 67(21):10573-81. PubMed ID: 17975002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis.
    Atochina-Vasserman EN; Guo CJ; Abramova E; Golden TN; Sims M; James ML; Beers MF; Gow AJ; Krymskaya VP
    Am J Respir Cell Mol Biol; 2015 Jul; 53(1):96-104. PubMed ID: 25474372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
    Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
    Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.